In the latest episode of Inside Forbes India Podcast, Naini Thaker discusses her deep-dive profile on Dilip Shanghvi, the low-key founder of Sun Pharma, India's largest pharmaceutical company. Starting with just $200, Shanghvi's strategic focus on chronic therapies and acquisitions helped shape Sun Pharma into a global force. The conversation explores how the company weathered challenges by doubling down on R&D and pivoting toward complex specialty drugs. Here's how Shanghvi's leadership is marked by humility and a focus on patient care rather than wealth accumulation